Selected stock price target news of the day - October 10th, 2025

By: Matthew Otto

Delta Air Lines Exceeds Q3 Earnings Estimates, Forecasts Strong Finish to 2025

Delta Air Lines reported third-quarter earnings that surpassed Wall Street expectations, posting earnings per share (EPS) of $1.71, $0.18 higher than the analyst estimate of $1.53. Revenue reached $15.2 billion, above the consensus forecast of $15.04 billion, and up 4% from the same quarter last year. Net income rose 11% to $1.42 billion, or $2.17 per share, while adjusted profit increased 15% to $1.12 billion.

The airline’s results were driven by steady domestic demand and continued strength in premium travel, which generated nearly $5.8 billion in revenue—9% higher year over year. In contrast, main cabin sales fell 4% to around $6 billion. Domestic unit revenue rose 2% during the quarter, supported by a 5% increase in overall domestic passenger revenue and an 8% rebound in corporate travel.

Looking ahead, Delta expects fourth-quarter EPS between $1.6 and $1.9, above the $1.65 analysts had projected, and sees revenue growth of 2% to 4% year over year, compared with Wall Street’s forecast of 1.7%. For the full year, the carrier projects adjusted EPS of $6—above the consensus estimate of $5.77 and at the upper end of its July guidance range.

Analysts Boost Delta Ratings and Price Targets by 9.3% After Q3 Results

Bernstein analyst David Vernon maintained Outperform rating while lifting the price target from $71 to $74.
Deutsche Bank analyst Michael Linenberg reiterated a Buy rating and boosted the price target from $63 to $72.

Which Analyst has the best track record to show on DAL?

Analyst Thomas Wadewitz (UBS) currently has the highest performing score on DAL with 1/8 (12.5%) price target fulfillment ratio. His price targets carry an average of $15.55 (27.55%) potential upside. Delta Air Lines stock price reaches these price targets on average within 2 days.

OrthoPediatrics Reports Preliminary Q3 Revenue Growth and Revises 2025 Financial Guidance

OrthoPediatrics Corp. reported preliminary unaudited third-quarter 2025 revenue of approximately $61.2 million, reflecting a 12% increase from the $54.6 million recorded in the same quarter last year.

Domestic revenue grew by 14% to around $48.7 million, while international sales rose 6% to $12.5 million, partly impacted by delayed set and stocking orders in Latin and South America. Excluding 7D capital sales, total revenue was $60.7 million, up 17% year-over-year, with domestic revenue in that category increasing 19% to $48.2 million.

OrthoPediatrics reported that it supported over 37,100 children during the quarter, bringing its cumulative total to approximately 1.3 million children since its founding.

For full-year 2025, OrthoPediatrics now expects revenue between $233.5 million and $234.5 million, down from its previous forecast of $237 million to $242 million, representing 14% to 15% growth over 2024. The company maintained expectations for $15 million in annual set deployment and an adjusted EBITDA range of $15 million to $17 million.

Analyst Ratings Stay Positive as Price Targets for OrthoPediatrics Are Cut by an Average of 35%

Piper Sandler analyst Matt O’Brien maintained an Overweight rating but lowered the price target from $30 to $22.
BTIG analyst Ryan Zimmerman reiterated a Buy rating while reducing the price target from $39 to $23.
Stifel analyst Rick Wise cut the price target from $32 to $20.

Which Analyst has the best track record to show on KIDS?

Analyst Richard Newitter (TRUIST) currently has the highest performing score on KIDS with 5/10 (50%) price target fulfillment ratio. His price targets carry an average of $2.84 (13.42%) potential upside. OrthoPediatrics Corp. stock price reaches these price targets on average within 22 days.

Nurix Therapeutics Reports Wider Q3 Loss and Advances Clinical Pipeline Toward Pivotal Trials

Nurix Therapeutics reported a net loss of $86.4 million, or ($1.03) per share, for the fiscal third quarter ended August 31, 2025, missing analyst expectations of ($0.83) by $0.2. Quarterly revenue totaled $7.89 million, falling short of the $16.05 million consensus estimate and down from $12.6 million a year earlier. The decrease was largely tied to the conclusion of certain research terms within its Sanofi collaboration.

Research and development expenses rose to $86.1 million from $55.5 million as Nurix expanded clinical trials and manufacturing operations. General and administrative costs increased to $13.2 million from $11.7 million, while cash, cash equivalents, and marketable securities stood at $428.8 million at quarter’s end, compared with $609.6 million as of November 2024.

Nurix plans to initiate pivotal trials for its lead drug candidate, bexobrutideg, in the second half of 2025 for patients with relapsed or refractory chronic lymphocytic leukemia (CLL), a condition affecting about 20,000 people annually in the United States and more than 200,000 globally. Current estimates suggest that roughly one-third of CLL patients eventually relapse after standard therapies, indicating that more than 60,000 individuals worldwide could benefit from improved treatment options.

In Phase 1 data, bexobrutideg achieved an overall response rate of 80.9% among 47 CLL patients, including one complete response, and 84.2% among 19 patients with Waldenström macroglobulinemia, which affects around 1,000 new patients each year in the U.S. In collaboration with Gilead, Nurix presented preclinical findings for GS-6791, an IRAK4 degrader, showing strong inhibition of inflammatory pathways relevant to dermatitis—a disease impacting over 31 million Americans.

Analysts Maintain Ratings, Adjust Price Targets lower

Oppenheimer analyst Matthew Biegler maintained an Outperform rating but lowered the price target from $30 to $28.
Piper Sandler analyst Joseph Catanzaro kept an Overweight rating yet cut the price target from $35 to $32.
Leerink Partners analyst Faisal Khurshid maintained a neutral stance but reduced the price target from $16 to $12.

Which Analyst has the best track record to show on NRIX?

Analyst Terence Flynn (MORGAN STANLEY) currently has the highest performing score on NRIX with 4/5 (80%) price target fulfillment ratio. His price targets carry an average of $3.85 (31.69%) potential upside. Nurix Therapeutics stock price reaches these price targets on average within 162 days.